Peter Greenleaf - 02 Mar 2022 Form 4 Insider Report for Aurinia Pharmaceuticals Inc. (AUPH)

Source evidence 5 source fields
Form type
4
Accepted by SEC
04 Mar 2022, 15:11:27 UTC
Previous filing
31 Jan 2022
Next filing
22 Mar 2022
SEC filing
View on sec.gov
Reporting owner 1 detail
Reporting owner signature
/s/ Peter S. Greenleaf

Key filing fact

Peter Greenleaf filed Form 4 for Aurinia Pharmaceuticals Inc. (AUPH) on 04 Mar 2022.

Key facts

  • This page summarizes Peter Greenleaf's Form 4 filing for Aurinia Pharmaceuticals Inc. (AUPH).
  • 4 reported transactions and 2 derivative rows are listed below.
  • Accepted by SEC: 04 Mar 2022, 15:11.

Change

  • Previous filing in this sequence was filed on 31 Jan 2022.
  • Current net transaction value: -$108,907.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

See Original Filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AUPH transaction

Common Stock

Award

Transaction value
$0
Shares
+28,300
Change %
+206%
Price
$0.000000
Shares after
42,035
Date
02 Mar 2022
Ownership
Direct
Footnotes
F1, F2
AUPH transaction

Common Stock

Sale

Transaction value
$108,907
Shares
-9,068
Change %
-22%
Price
$12.01
Shares after
32,967
Date
02 Mar 2022
Ownership
Direct
Footnotes
F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AUPH transaction Derivative

Restricted Stock Unit

Award

Transaction value
$0
Shares
+312,240
Change %
Price
$0.000000
Shares after
312,240
Date
02 Mar 2022
Ownership
Direct
Underlying class
Common Shares
Underlying amount
312,240
Exercise price
Footnotes
F4
AUPH transaction Derivative

Stock Option (right to buy)

Award

Transaction value
$0
Shares
+534,188
Change %
Price
$0.000000
Shares after
534,188
Date
02 Mar 2022
Ownership
Direct
Underlying class
Common Stock
Underlying amount
534,188
Exercise price
$12.01
Footnotes
F5
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

On March 18, 2021, the Reporting Person was granted stock based performance awards ("Performance Awards") which vests when specific performance metrics are met based on the results for the year ended December 31, 2021. It was determined that as of March 2, 2022, the Reporting Person partially met the performance criteria and received shares of common stock for no consideration.

Footnote F2

Includes 282 shares acquired by the Reporting Person under the Issuer's 2021 Employee Share Purchase Plan on December 1, 2021.

Footnote F3

Represents the number of shares sold to cover tax withholding obligations in connection with the vesting of Performance Awards.

Footnote F4

Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in three (3) equal annual installments beginning March 2, 2022, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date.

Footnote F5

One-third of the shares subject to the option vests twelve months from the grant date, and the remainder vests in twenty-four equal monthly installments thereafter.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .